The ongoing shortage of prescription stimulants, such as Adderall, is being addressed by the Drug Enforcement Administration (DEA) and Food and Drug Administration (FDA). These medications, commonly used to treat ADHD and narcolepsy, have been in short supply since last fall due to manufacturing delays by a major drug maker.
While the manufacturing delays have been resolved, FDA Commissioner Robert Califf and DEA Administrator Anne Milgram highlighted in a letter addressed to the American public that the shortage has been prolonged and worsened by the increased use of prescription stimulants during the COVID-19 pandemic.
To tackle the issue, Califf and Milgram are urging drug manufacturers to increase production of prescription stimulants to meet their annual quotas. They are also calling on those who do not wish to boost production to surrender the remainder of their allotted quota for redistribution. Currently, pharmaceutical companies only sold about 70% of their quota last year and are following a similar trend this year.
It’s important to note that the FDA and DEA cannot force pharmaceutical companies to produce more drugs, but they are working closely with manufacturers, agencies, and the supply chain to understand, prevent, and reduce the impact of the shortages.
The FDA is also encouraging professional groups and healthcare providers to support the appropriate diagnosis and treatment of ADHD. The goal is to ensure that those in need of stimulant medications have access while ensuring responsible and thoughtful prescribing practices.
In conclusion, the DEA and FDA are taking steps to address the shortage of prescription stimulants and are calling on drug manufacturers to increase production. They are also advocating for responsible prescribing practices and support for appropriate diagnosis and treatment of ADHD.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
